Inflammation, cytokines and anti-inflammatory therapies in heart failure.
Both experimental and clinical studies have shown a role for inflammation in the pathogenesis of heart failure. This seems related to an imbalance between pro-inflammatory and anti-inflammatory cytokines. Certain categories in patients with dilated cardiomyopathy have shown the presence of humoral and cellular immunity activation suggesting a possible relation between myocarditis and dilated cardiomyopathy. Recent studies suggest a link between the circulating levels of cytokines (TNF alpha IL-1 et IL-6), the clinical status and prognostic. However, the mechanisms connecting heart failure and cytokine activation are unclear and the sites of cytokines production remain controversial. In the clinical setting, specific measurements of cytokines are not available. As tests of inflammation, erythrocyte sedimentation rate and C-reactive protein concentration appear to have interesting pronostic values. Current conventional therapy i.e. ACE inhibitors, type I angiotensin II antagonist and beta-blockers have shown some anti-cytokine properties. Recently, immunosuppressive therapies have shown their ability to improve symptoms and LV ejection in selected patients with dilated cardiomyopathy and clear sign of myocardium inflammation. Specific anti-cytokine therapy have been developed and showed interesting results in preliminary clinical studies. However large clinical trials testing this new therapy have been stoppel prematurely because of deterious effects.
Tabet
J Y
JY
Fédération des services de cardiologie et service de médecine nucléaire, INSERM U400, centre de recherches chirurgicales, hôpital Henri Mondor, 94010 Créteil.
Lopes
M E
ME
Champagne
S
S
Su
J B
JB
Merlet
P
P
Hittinger
L
L
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D002311:Cardiomyopathy, Dilated / Q000276:immunology / Q000473:pathology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000494:pharmacology* / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000473:pathology*; D009205:Myocarditis / Q000276:immunology / Q000473:pathology; D011379:Prognosis
D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D016207:Cytokines; D007166:Immunosuppressive Agents